ProShare Advisors
EIKN

ProShare Advisors’s Eikon Therapeutics EIKN Stock Holding History

ProShare Advisors’s Portfolio EIKN Stock Details EIKN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$387K Buy
+29,685
New +$303K ﹤0.01% 1262

Other funds holding EIKN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $526M AUM 175.27% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return

ProShare Advisors's EIKN Position: Q2 2026 in Review

ProShare Advisors opened a new position in Eikon Therapeutics (EIKN) in Q2 2026: 29,685 shares worth $387K. The stake represents ﹤0.01% of the portfolio and ranks #1262 among its holdings.

35 funds tracked by Wall St. Rank hold EIKN as of Q2 2026.

  • ProShare Advisors held 29,685 shares of Eikon Therapeutics worth $387K as of Q2 2026.
  • Eikon Therapeutics was a new ProShare Advisors position in Q2 2026.
  • Eikon Therapeutics made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #1262 holding.
  • 35 funds tracked by Wall St. Rank held Eikon Therapeutics as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.